A budget impact model of third-line or later trifluridine/tipiracil treatment of metastatic colorectal cancer.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e15070
Abstract: e15070Background: Trifluridine/tipiracil (FTD/TPI) was recently approved for the treatment of third-line or later (3L+) metastatic colorectal cancer (mCRC). The objective of this study was to devel... read more here.
Keywords: metastatic colorectal; line later; trifluridine tipiracil; third line ... See more keywords